Propranolol ve kanser

Year 2018, Volume: 3 Issue: 1-2, 31 - 37, 04.04.2019

Zehra Pınar Cengiz , Oytun Erbaş

Abstract

Propranolol hipertansiyondan benign infantil hemanjiyom tedavisine kadar klinik etkiler gösteren ve günümüzde daha agresif vasküler sarkomlar ve diğer kanserler için kullanılan bir beta adrenerjik reseptör inhibitörüdür. Spesifik olmayan beta adrenerjik bloklayıcı bir ilaç olan propranolol, katekolaminlerin reseptörlere bağlanmasını ve kanser hücrelerinin çoğalmasını önler. Bu nedenle, onkolojide önemli bir geri dönüşüm adayıdır. Propranololün anti-tümör aktivitesi, farklı kanser türlerinde tedavi ve profilaksi amacıyla kullanılabilir. Bu derlemede, propranol'ün hemanjiyom, meme, pankreas ve prostat kanserleri üzerindeki profilaktik etkileri tartışıldı.

Keywords

Kanser, beta bloker, profilaksi, propranolol

References

• 1. Pantziarka P, Bryan BA, Crispino S, Dickerson EB. Propranolol and breast cancer-a work in progress. Ecancermedicalscience 2018;12:82. 2. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51. 3. Finkel R, Clark MA, Cubeddu LX, editors. Lippincott’s illustrated reviews: Pharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. 4. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369-75. 5. Dilek M, Bekda M, Bilir Göksügür S, Demircio¤lu F, Karata Z, Erkoço¤lu M ve ark. ‹nfantil hemanjiom ve oral propranolol tedavisi. ili Etfal Hastanesi Tıp Bülteni 2015;49:148-51. 6. De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, et al. Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. JAMA Oncol 2018;4:172908. 7. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience 2014;8:442. 8. Karaca ‹, Türk E, Mee T, Demira¤ B, Faytoncu . The use of proprano-lol as first-line treatment of infantile hemangioma: Case presentation. ‹zmir Dr. Behçet Uz Çocuk Hast Derg 2014;4:65-8. 9. Torun YA, Ergül AB, Dursun ‹. Propranolol infantil hemanjiomda birinci basamak tedavisi olarak kullanılabilir mi. Dicle Medical Journal 2011;38:95-7. 10. Kozanoglu I, Yandim MK, Cincin ZB, Ozdogu H, Cakmakoglu B, Baran Y. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. J Cancer Res Clin Oncol 2013;139:327-35. 11. Mendiratta V, Jabeen M. Infantile hemangioma: an update. Indian J Dermatol Venereol Leprol 2010;76:469-75. 12. Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124:423-31. 13. Do¤ramacı AÇ, Bails S. Hemangiomas of in-fancy. Turkiye Klinikleri J Dermatol 2008;18:160-5. 14. Bautch VL. VEGF-directed blood vessel patterning: from cells to organism. Cold Spring Harb Perspect Med 2012;2:a006452. 15. Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics 2013;131:99-108. 16. Albiñana V, Escribano RMJ, Soler I, Padial LR, Recio-Poveda L, Villar Gómez de Las Heras K, et al. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet J Rare Dis 2017;12:122. 17. Zhu L, Xie J, Liu Z, Huang Z, Huang M, Yin H, et al. Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol. Cancer Sci 2018;109:1981-994. 18. Wrobel LJ, Le Gal FA. Inhibition of human melanoma growth by a non-cardioselective b-blocker. J Invest Dermatol 2015;135:525-31. 19. Xu T, Xiao X, Zheng S, Zheng J, Zhu H, Ji Y, et al. Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice. J Pediatr Surg 2013;48:2460-5. 20. Zhang L, Mai HM, Zheng J, Zheng JW, Wang YA, Qin ZP, et al. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. Int J Clin Exp Pathol 2013;7:48-55. 21. Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003;98:1716-26. 22. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol 2010;11:983-91. 23. Sher SJ, Mujtaba MA, Yaqub MS, Taber TE, Mishler DP, Sharfuddin AA. Early Fatal Cutaneous Lower Extremity Angiosarcoma Associated with Deep Venous Thrombosis in a Renal Transplant Recipient. Exp Clin Transplant 2017;15:463-6. 24. Chow W, Amaya CN, Rains S, Chow M, Dickerson EB, Bryan BA. Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated b-Blockade. JAMA Dermatol 2015;151:1226-9. 25. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 2011;29:2635-44. 26. Herrera I, Pascual S, Zapater P, Carnicer F, Bellot P, María Palazón J. The use of b-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis. Eur J Gastroenterol Hepatol 2016;28:1194-7. 27. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008;15:2042-52. 28. Choy C, Raytis JL, Smith DD, Duenas M, Neman J, Jandial R, et al. Inhibition of b2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative b-blockade. Oncol Rep 2016;35:3135-42. 29. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1:628-38. 30. Rico M, Baglioni M, Bondarenko M, Laluce NC, Rozados V, André N, et al. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget 2017;8:2874-89. 31. Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL, et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 2012;10:1001363. 32. Elefteriou F. Chronic stress, sympathetic activation and skeletal metastasis of breast cancer cells. Bonekey Rep 2015;4:693. 33. Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009;20:477-82. 34. Brohée L, Peulen O, Nusgens B, Castronovo V, Thiry M, Colige AC, et al. Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression. Sci Rep 2018;8:7050.